Thirteen patients in a cohort of 340 cancer patients who received genetically modified immune cells developed 16 secondary cancers in the months or years following treatment, a rate comparable to patients who receive standard-of-care therapies, including chemotherapy and hematopoietic stem cell transplant. Researchers reviewed biopsy results for 11 of the secondary tumors and found no transferred genetic material from the therapy.
/PRNewswire/ EmpiraMed, Inc., a digital health technology leader in the field of Virtual Clinical Studies for Real World Evidence, today announced that.
Zephyr® Valve Treatment Provides Long-Term Quality of Life globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Novartis Pharma AG: New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.